- Home
- ROIV vs FWONK Comparison
ROIV vs FWONK Comparison
Compare ROIV & FWONK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | FWONK |
|---|---|---|
| Founded | 2014 | 1950 |
| Country | United Kingdom | United States |
| Employees | N/A | 1674 |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 22.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | FWONK |
|---|---|---|
| Price | $27.08 | $88.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $28.94 | ★ $110.88 |
| AVG Volume (30 Days) | ★ 4.5M | 1.6M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,053,000.00 | N/A |
| Revenue This Year | N/A | $24.56 |
| Revenue Next Year | $744.61 | $5.52 |
| P/E Ratio | ★ N/A | $107.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.58 | $80.15 |
| 52 Week High | $30.33 | $109.36 |
Technical Indicators
Market Signals| Indicator | ROIV | FWONK |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 53.07 |
| Support Level | $26.94 | $81.84 |
| Resistance Level | $27.94 | $90.85 |
| Average True Range (ATR) | 0.85 | 2.11 |
| MACD | -0.12 | -0.06 |
| Stochastic Oscillator | 14.42 | 47.74 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About FWONK Liberty Media Corporation Series C Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. It operates in two reportable segment Formula 1 and MotoGP. It generates majority of its revenue from the Formula 1 segment. The company derives its maximum revenue from United Kingdom.